Allergy Therapeutics “double digit growth” says Manuel Llobet, CEO

Commenting on the trading update, Manuel Llobet, Chief Executive Officer, said: “We are delivering double digit growth at constant currency and gaining market share despite a flat to low European market. Overall we are executing our business strategy and, in addition to growing our European business, remain focused on executing a pivotal clinical trial programme, potentially paving the way towards the US and expanding into new market segments with a strong new product pipeline. Our business is now in a very strong position to generate continuing growth over the coming years.”

*Constant currency uses prior year weighted average exchange rates to translate current year foreign currency denominated revenue to give a year on year comparison excluding the effects of foreign exchange movements. Without using the constant currency effect, the Company expects first half reported revenues of approximately GBP29.0m (H1 2015: GBP28.2m), representing growth of 3 per cent.; the negative impact from the weakening Euro being GBP2.5m.

 

Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today gave DirectorsTalk a trading update for the six months to 31 December 2015, ahead of the publication of its unaudited interim results in March 2016.

At *constant currency the Company expects to report revenue growth of 12 per cent. for the period, with first half revenues of approximately GBP31.5m (H1 2015: GBP28.2m). This double digit organic sales growth has been primarily driven by the Company’s positive trading performance as it continues to increase its market share in all of its major European markets, supported by the acquisition of Alerpharma in June 2015. It is therefore anticipated that the Company’s full year revenue will be in-line with current market expectations despite significant currency headwinds.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
Allergy therapeutics plc

More articles like this

Allergens dominate UK food recalls, finds study

More than half of food recalls in the United Kingdom over a 5-year period were due to allergens, according to a recently released study. Allergen-related recalls increased annually until 2019, peaking at 118 before decreasing to

Allergy Therapeutics welcomes new Non-Executive Directors

Allergy Therapeutics announced the appointments of Anthony Parker and Simon Shen to its Board as Non-Executive Directors effective immediately. “I would like to welcome Anthony and Simon. Southern Fox and ZQ Capital have been long-standing and supportive shareholders of Allergy

Allergy Therapeutics updates on its clinical programmes

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced that the first subject has been dosed in the pivotal Phase III G306 trial, to evaluate the efficacy and safety of

Allergy Therapeutics appoints two Non-Executive Directors

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has today announced the appointments of Anthony Parker and Zheqing (Simon) Shen as Non-Executive Directors of the Company, with immediate effect. Anthony represents

Allergies and Thanksgiving

As Thanksgiving and other holiday celebrations bring people around the table, Intermountain Healthcare dietitians say it’s crucial to take food allergies into consideration when planning the big meal. “A response to an allergic reaction can be

Allergy Therapeutics appoints Martin Hopcroft as interim CFO

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced the appointment of Martin Hopcroft to the role of Interim Chief Financial Officer (CFO). Martin will report into Chief Executive

Food business operator fined for allergy breach

A food business operator based in Newcastle, England has been fined in court after serving a dish containing peanuts to a woman with a peanut allergy, resulting in her being hospitalised. According to the Food Standards

Are restaurants taking allergies seriously?

In an engaging panel held at Twickenham Stadium as part of New Food’s Food Safety Conference 2022, experts came together to debate whether food allergy regulations in restaurants are sufficient. Here’s the highlights. Are restaurant allergy

Allergy Therapeutics Subscription to raise £7 million

Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical company specialising in allergy immunotherapy, today announces a conditional Subscription by the Subscribers, Southern Fox and ZQ Capital (acting through its affiliate SkyGem), to raise £7 million